AI-generated · cited to primary sources · not investment advice
Johnson & Johnson Common Stock (JNJ) Jun 2025 Filing Analysis
Does management do what it says?
The company maintained its dividend commitment, paying $1.30 per share in Q3 2025 and declaring an identical amount for Q4 2025. (1 met across 1 tracked commitment)
“On July 16, 2025, the Board of Directors declared a regular cash dividend of $1.30 per share... The Company expects to continue the practice of paying regular quarterly cash dividends.”
Management delivered on the expected re-measurement cost following the enactment of the OBBBA, recording a one-time cost of approximately $1.0 billion in the fiscal third quarter of 2025. (2 met across 2 tracked commitments)
“The Company will remeasure its deferred tax balances related to NCTI for the changes in the tax rate and will record an adjustment to this balance in the fiscal third quarter. The Company is still assessing this impact but is estimating this one-time re-measurement cost to be approximately $1.0 billion.”
See the full cited Management analysis of Johnson & Johnson Common Stock
How durable is the business?
The company utilized its balance sheet strength to complete the $14.5 billion acquisition of Intra-Cellular Therapies, adding the mental health drug CAPLYTA to its portfolio. This resulted in a decrease in cash and an increase in long-term debt. (2 shifted, 1 exited)
“Cash and cash equivalents (Note 4) $18,577 24,105”
See the full cited Business Model analysis of Johnson & Johnson Common Stock
What could break the thesis?
The risk is stable as litigation remains ongoing, but the company notes that Medicare Part D redesign is already negatively impacting sales of several key products like IMBRUVICA and XARELTO. (1 stable)
“The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing”
The risk is intensifying as biosimilar competition is now a primary driver of revenue decline in the Immunology segment, with a 42.7% drop in STELARA sales this quarter. (2 intensifying)
“Immunology products experienced an operational decline of 16.0%... primarily due to the decline of STELARA (ustekinumab) sales driven by the impact of biosimilar competition”
See the full cited Risk analysis of Johnson & Johnson Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.